Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18M Buy
148,433
+10,688
+8% +$1.23M 0.23% 83
2025
Q4
$14.6M Buy
137,745
+17,528
+15% +$1.65M 0.21% 91
2025
Q3
$10.1M Buy
120,217
+1,688
+1% +$139K 0.15% 125
2025
Q2
$9.48M Buy
118,529
+18,356
+18% +$1.46M 0.21% 87
2025
Q1
$8.99M Sell
100,173
-1,926
-2% -$180K 0.25% 74
2024
Q4
$10.2M Buy
102,099
+25,997
+34% +$2.68M 0.36% 50
2024
Q3
$8.7M Buy
76,102
+34,986
+85% +$4.16M 0.34% 52
2024
Q2
$5.12M Buy
41,116
+15,722
+62% +$2.03M 0.23% 68
2024
Q1
$3.37M Buy
25,394
+3,012
+13% +$371K 0.2% 66
2023
Q4
$2.46M Buy
22,382
+2,898
+15% +$301K 0.16% 86
2023
Q3
$2.02M Buy
19,484
+10,702
+122% +$1.15M 0.15% 88
2023
Q2
$1.02M Buy
8,782
+3,155
+56% +$358K 0.07% 152
2023
Q1
$603K Sell
5,627
-247
-4% -$26.7K 0.05% 158
2022
Q4
$652K Sell
5,874
-85
-1% -$8.69K 0.06% 149
2022
Q3
$517K Buy
5,959
+2,880
+94% +$257K 0.05% 166
2022
Q2
$283K Sell
3,079
-11,393
-79% -$1.01M 0.03% 205
2022
Q1
$1.2M Buy
14,472
+2,227
+18% +$176K 0.09% 102
2021
Q4
$947K Buy
12,245
+96
+0.8% +$7.65K 0.07% 113
2021
Q3
$920K Sell
12,149
-1,226
-9% -$93.2K 0.08% 88
2021
Q2
$1.05M Buy
+13,375
New +$995K 0.1% 48

Other funds holding MRK

Summit Financial's MRK Position: Q1 2026 in Review

Summit Financial increased its Merck (MRK) stake by 7.8% in Q1 2026, buying an estimated $1.23M and bringing the position to 148,433 shares worth $18M. The position accounts for 0.23% of the portfolio, ranked #83.

Summit Financial first reported a position in MRK in Q2 2021 and has held it in 20 quarters since. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Summit Financial held 148,433 shares of Merck worth $18M as of Q1 2026.
  • Summit Financial bought 10,688 Merck shares in Q1 2026, an estimated $1.23M.
  • Merck made up 0.23% of Summit Financial's portfolio in Q1 2026, its #83 holding.
  • Summit Financial first reported a position in Merck in Q2 2021 and has held it in 20 quarters since.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.